Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Bullous Pemphigoid (FJORD)
NCT04612790Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of benralizumab in Bullous Pemphigoid (BP), sponsored by AstraZeneca. Started Mar 2021; status: terminated.
02
Drugs
benralizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04612790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612790.